Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
Pebble Responds To U.S. Supreme Court Decision To Deny Alaska’s Petition; Says “While It Is A Disappointing Decision, It Is Important To Note That This Is Not A Comment On The Arguments Put Forward By The State.”
Northern Dynasty Minerals Ltd. (TSX:NDM)(NYSE:NAK) ("Northern Dynasty" or the "Company") reports that the US Supreme Court has denied Alaska's petition to review its claims that the EPA veto of the Pebble Project was
